Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Coronary Syndrome | 31 | 2023 | 2337 | 5.580 |
Why?
|
Ticlopidine | 13 | 2022 | 899 | 2.550 |
Why?
|
Anticholesteremic Agents | 9 | 2024 | 979 | 2.340 |
Why?
|
Myocardial Infarction | 36 | 2024 | 11727 | 2.250 |
Why?
|
Platelet Aggregation Inhibitors | 24 | 2023 | 3068 | 2.030 |
Why?
|
Lipoprotein(a) | 6 | 2022 | 435 | 1.870 |
Why?
|
Benzaldehydes | 8 | 2018 | 58 | 1.840 |
Why?
|
Oximes | 8 | 2018 | 311 | 1.620 |
Why?
|
Purinergic P2Y Receptor Antagonists | 5 | 2022 | 361 | 1.610 |
Why?
|
Pyridines | 11 | 2021 | 2825 | 1.590 |
Why?
|
Atherosclerosis | 9 | 2023 | 3445 | 1.540 |
Why?
|
Hemorrhage | 12 | 2023 | 3461 | 1.350 |
Why?
|
Angina, Unstable | 5 | 2020 | 926 | 1.150 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2023 | 3255 | 1.150 |
Why?
|
Heart Failure | 23 | 2023 | 10900 | 1.140 |
Why?
|
Cardiovascular Diseases | 20 | 2023 | 15165 | 1.060 |
Why?
|
Imines | 4 | 2012 | 33 | 1.030 |
Why?
|
Thiophenes | 5 | 2013 | 588 | 0.960 |
Why?
|
Sex Characteristics | 6 | 2023 | 2585 | 0.950 |
Why?
|
Cyclopropanes | 2 | 2016 | 416 | 0.950 |
Why?
|
Double-Blind Method | 22 | 2022 | 12026 | 0.940 |
Why?
|
Natriuretic Peptide, Brain | 11 | 2023 | 1573 | 0.940 |
Why?
|
Women | 3 | 2021 | 230 | 0.930 |
Why?
|
Coronary Artery Disease | 14 | 2024 | 6487 | 0.910 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 3 | 2021 | 697 | 0.880 |
Why?
|
Stroke | 14 | 2024 | 9981 | 0.850 |
Why?
|
Guilt | 1 | 2022 | 95 | 0.800 |
Why?
|
Coronary Restenosis | 2 | 2021 | 424 | 0.770 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 68 | 0.770 |
Why?
|
Calgranulin A | 1 | 2021 | 79 | 0.760 |
Why?
|
Lactones | 3 | 2019 | 329 | 0.750 |
Why?
|
Calgranulin B | 1 | 2021 | 84 | 0.750 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 5 | 2018 | 127 | 0.750 |
Why?
|
Phospholipases A | 2 | 2014 | 216 | 0.710 |
Why?
|
Platelet Function Tests | 2 | 2021 | 270 | 0.700 |
Why?
|
Judgment | 1 | 2022 | 281 | 0.690 |
Why?
|
Heptanoic Acids | 2 | 2014 | 343 | 0.650 |
Why?
|
Pravastatin | 2 | 2014 | 395 | 0.650 |
Why?
|
P-Selectin | 1 | 2021 | 600 | 0.650 |
Why?
|
Piperazines | 5 | 2013 | 2488 | 0.640 |
Why?
|
Thrombolytic Therapy | 6 | 2013 | 2161 | 0.620 |
Why?
|
Drug Therapy | 1 | 2021 | 497 | 0.610 |
Why?
|
Fatty Acid-Binding Proteins | 3 | 2013 | 300 | 0.610 |
Why?
|
Fatty Acids, Omega-3 | 3 | 2023 | 1344 | 0.610 |
Why?
|
Cystatin C | 1 | 2018 | 250 | 0.600 |
Why?
|
Hypercholesterolemia | 2 | 2022 | 1151 | 0.600 |
Why?
|
Glomerular Filtration Rate | 6 | 2022 | 2170 | 0.600 |
Why?
|
Receptors, Thrombin | 3 | 2014 | 131 | 0.590 |
Why?
|
Secondary Prevention | 7 | 2019 | 1530 | 0.590 |
Why?
|
Proton Pump Inhibitors | 3 | 2013 | 526 | 0.590 |
Why?
|
Glucosides | 1 | 2021 | 451 | 0.580 |
Why?
|
Drug-Eluting Stents | 2 | 2021 | 753 | 0.550 |
Why?
|
CD40 Ligand | 2 | 2021 | 526 | 0.540 |
Why?
|
Diabetic Angiopathies | 3 | 2016 | 818 | 0.520 |
Why?
|
Peptide Fragments | 9 | 2023 | 5097 | 0.520 |
Why?
|
Risk Assessment | 16 | 2021 | 23338 | 0.510 |
Why?
|
Death, Sudden, Cardiac | 3 | 2021 | 1541 | 0.510 |
Why?
|
Humans | 119 | 2024 | 744343 | 0.510 |
Why?
|
Sleep Disorders, Circadian Rhythm | 1 | 2017 | 222 | 0.500 |
Why?
|
Treatment Outcome | 35 | 2024 | 63114 | 0.500 |
Why?
|
Galectin 3 | 2 | 2016 | 227 | 0.500 |
Why?
|
Benzhydryl Compounds | 1 | 2021 | 845 | 0.500 |
Why?
|
Platelet Activation | 4 | 2016 | 673 | 0.480 |
Why?
|
Thrombosis | 3 | 2023 | 2968 | 0.480 |
Why?
|
Pyrroles | 2 | 2014 | 1146 | 0.470 |
Why?
|
Aspirin | 5 | 2022 | 3282 | 0.470 |
Why?
|
Coronary Disease | 4 | 2018 | 6077 | 0.470 |
Why?
|
Cholesterol, LDL | 8 | 2023 | 2356 | 0.470 |
Why?
|
Adenosine Monophosphate | 1 | 2016 | 275 | 0.470 |
Why?
|
Male | 73 | 2024 | 350118 | 0.450 |
Why?
|
Female | 78 | 2024 | 380194 | 0.450 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2021 | 9959 | 0.450 |
Why?
|
RNA, Small Interfering | 1 | 2022 | 3505 | 0.450 |
Why?
|
Blood Proteins | 2 | 2016 | 1124 | 0.440 |
Why?
|
Blood Platelets | 6 | 2023 | 2508 | 0.440 |
Why?
|
Cardiovascular Agents | 2 | 2021 | 850 | 0.440 |
Why?
|
Risk Factors | 35 | 2024 | 72290 | 0.430 |
Why?
|
Ischemia | 1 | 2021 | 1907 | 0.430 |
Why?
|
Acetates | 1 | 2014 | 311 | 0.430 |
Why?
|
Middle Aged | 54 | 2022 | 213383 | 0.420 |
Why?
|
Thiazoles | 2 | 2021 | 1483 | 0.420 |
Why?
|
Fibroblast Growth Factors | 1 | 2018 | 879 | 0.420 |
Why?
|
Dyspnea | 8 | 2008 | 1303 | 0.420 |
Why?
|
Aged | 51 | 2024 | 163280 | 0.410 |
Why?
|
Electrocardiography | 4 | 2021 | 6442 | 0.400 |
Why?
|
Phospholipases A2, Secretory | 1 | 2011 | 31 | 0.400 |
Why?
|
Communication Barriers | 1 | 2014 | 398 | 0.400 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2009 | 1873 | 0.380 |
Why?
|
Interleukin-18 | 1 | 2012 | 249 | 0.380 |
Why?
|
Atrial Fibrillation | 6 | 2023 | 5034 | 0.380 |
Why?
|
Adenosine | 1 | 2015 | 825 | 0.370 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 690 | 0.370 |
Why?
|
Receptor, PAR-1 | 3 | 2019 | 113 | 0.360 |
Why?
|
Myocardial Revascularization | 3 | 2016 | 841 | 0.350 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 257 | 0.350 |
Why?
|
Purinergic P2 Receptor Antagonists | 1 | 2009 | 71 | 0.340 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5535 | 0.340 |
Why?
|
Inflammation Mediators | 1 | 2017 | 1889 | 0.330 |
Why?
|
Indoles | 2 | 2014 | 1839 | 0.310 |
Why?
|
Kidney Diseases | 1 | 2019 | 2149 | 0.310 |
Why?
|
Interleukin-6 | 1 | 2017 | 3200 | 0.310 |
Why?
|
Proportional Hazards Models | 8 | 2019 | 12354 | 0.300 |
Why?
|
Platelet Aggregation | 4 | 2017 | 798 | 0.300 |
Why?
|
Kaplan-Meier Estimate | 5 | 2017 | 6538 | 0.300 |
Why?
|
Warfarin | 1 | 2015 | 1496 | 0.280 |
Why?
|
Recurrence | 5 | 2018 | 8340 | 0.270 |
Why?
|
Stents | 4 | 2022 | 3280 | 0.270 |
Why?
|
Plaque, Atherosclerotic | 1 | 2017 | 1519 | 0.270 |
Why?
|
Genome-Wide Association Study | 10 | 2022 | 12261 | 0.260 |
Why?
|
Women's Health | 1 | 2015 | 2034 | 0.260 |
Why?
|
Creatinine | 4 | 2022 | 1919 | 0.260 |
Why?
|
Genetic Pleiotropy | 2 | 2016 | 182 | 0.250 |
Why?
|
Disease Management | 1 | 2016 | 2459 | 0.250 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2017 | 1813 | 0.250 |
Why?
|
Prognosis | 13 | 2023 | 29063 | 0.240 |
Why?
|
Coronary Thrombosis | 2 | 2019 | 495 | 0.230 |
Why?
|
Troponin T | 3 | 2016 | 754 | 0.230 |
Why?
|
Renal Insufficiency | 2 | 2022 | 804 | 0.230 |
Why?
|
Evidence-Based Medicine | 2 | 2015 | 3610 | 0.230 |
Why?
|
Diabetes Mellitus | 2 | 2022 | 5751 | 0.230 |
Why?
|
Health Status Disparities | 1 | 2015 | 1797 | 0.220 |
Why?
|
Sex Factors | 4 | 2021 | 10397 | 0.220 |
Why?
|
Drug Interactions | 3 | 2013 | 1460 | 0.210 |
Why?
|
Subtilisins | 1 | 2022 | 83 | 0.210 |
Why?
|
N-Acetylgalactosaminyltransferases | 1 | 2022 | 65 | 0.210 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2021 | 11725 | 0.210 |
Why?
|
Multivariate Analysis | 6 | 2017 | 12245 | 0.210 |
Why?
|
Venous Thrombosis | 2 | 2022 | 1239 | 0.200 |
Why?
|
Sleep | 1 | 2017 | 4623 | 0.200 |
Why?
|
Acute Kidney Injury | 1 | 2014 | 1972 | 0.200 |
Why?
|
Pulmonary Embolism | 3 | 2023 | 2376 | 0.190 |
Why?
|
Anticoagulants | 2 | 2022 | 4599 | 0.190 |
Why?
|
Ceramides | 1 | 2022 | 199 | 0.190 |
Why?
|
Subtilisin | 1 | 2020 | 12 | 0.190 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2021 | 10943 | 0.190 |
Why?
|
Growth Differentiation Factor 15 | 2 | 2023 | 176 | 0.180 |
Why?
|
Databases, Factual | 1 | 2015 | 7729 | 0.180 |
Why?
|
Aortic Valve Stenosis | 2 | 2024 | 1965 | 0.180 |
Why?
|
Myocardium | 1 | 2012 | 4776 | 0.170 |
Why?
|
Drug Therapy, Combination | 5 | 2022 | 6489 | 0.170 |
Why?
|
Scavenger Receptors, Class B | 1 | 2018 | 81 | 0.170 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2020 | 179 | 0.160 |
Why?
|
Hospitalization | 5 | 2018 | 10262 | 0.160 |
Why?
|
Venous Thromboembolism | 2 | 2022 | 1671 | 0.160 |
Why?
|
Incidence | 5 | 2021 | 20947 | 0.160 |
Why?
|
Phospholipids | 1 | 2022 | 784 | 0.160 |
Why?
|
Oxytocin | 1 | 2022 | 394 | 0.160 |
Why?
|
Odds Ratio | 4 | 2017 | 9849 | 0.160 |
Why?
|
Interleukin-13 Receptor alpha1 Subunit | 1 | 2017 | 24 | 0.160 |
Why?
|
Postoperative Complications | 1 | 2020 | 15295 | 0.150 |
Why?
|
Antibodies, Monoclonal | 3 | 2022 | 9274 | 0.150 |
Why?
|
Genetic Variation | 3 | 2017 | 6544 | 0.150 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 4933 | 0.140 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2022 | 2208 | 0.140 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2019 | 386 | 0.140 |
Why?
|
Patients | 1 | 2023 | 900 | 0.140 |
Why?
|
C-Reactive Protein | 4 | 2016 | 3778 | 0.140 |
Why?
|
Adrenomedullin | 1 | 2016 | 87 | 0.140 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 1 | 2016 | 55 | 0.140 |
Why?
|
Quantitative Trait, Heritable | 1 | 2019 | 544 | 0.140 |
Why?
|
Withholding Treatment | 1 | 2020 | 599 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 841 | 0.130 |
Why?
|
Models, Biological | 1 | 2012 | 9583 | 0.130 |
Why?
|
Neutrophils | 1 | 2008 | 3719 | 0.130 |
Why?
|
Troponin I | 3 | 2013 | 619 | 0.130 |
Why?
|
Placebos | 2 | 2021 | 1676 | 0.130 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 913 | 0.130 |
Why?
|
Placebo Effect | 1 | 2019 | 502 | 0.130 |
Why?
|
Diabetic Nephropathies | 1 | 2022 | 984 | 0.130 |
Why?
|
Atrial Natriuretic Factor | 1 | 2016 | 393 | 0.130 |
Why?
|
Glycopeptides | 1 | 2016 | 224 | 0.130 |
Why?
|
Drug Monitoring | 1 | 2021 | 956 | 0.120 |
Why?
|
Risk | 3 | 2019 | 9687 | 0.120 |
Why?
|
Myocardial Ischemia | 2 | 2016 | 2148 | 0.120 |
Why?
|
Simvastatin | 1 | 2017 | 360 | 0.120 |
Why?
|
Obesity | 3 | 2022 | 12745 | 0.120 |
Why?
|
Quantitative Trait Loci | 2 | 2019 | 2019 | 0.120 |
Why?
|
Immune System Diseases | 1 | 2016 | 262 | 0.120 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2011 | 1518 | 0.120 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 7913 | 0.110 |
Why?
|
Galectins | 1 | 2016 | 268 | 0.110 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 3508 | 0.110 |
Why?
|
Predictive Value of Tests | 6 | 2011 | 15076 | 0.110 |
Why?
|
Aged, 80 and over | 10 | 2021 | 57776 | 0.110 |
Why?
|
Chest Pain | 2 | 2013 | 1114 | 0.110 |
Why?
|
Stroke Volume | 2 | 2006 | 5007 | 0.110 |
Why?
|
Peroxidase | 1 | 2016 | 611 | 0.110 |
Why?
|
Genetic Association Studies | 2 | 2019 | 2703 | 0.110 |
Why?
|
Proprotein Convertases | 1 | 2013 | 95 | 0.110 |
Why?
|
Dyslipidemias | 1 | 2020 | 849 | 0.110 |
Why?
|
Time Factors | 6 | 2020 | 40075 | 0.110 |
Why?
|
Bone Density Conservation Agents | 1 | 2019 | 773 | 0.100 |
Why?
|
Erythropoiesis | 1 | 2016 | 705 | 0.100 |
Why?
|
Patient Participation | 1 | 2021 | 1457 | 0.100 |
Why?
|
ROC Curve | 4 | 2008 | 3527 | 0.100 |
Why?
|
Protein Precursors | 1 | 2016 | 1154 | 0.100 |
Why?
|
Hypoglycemic Agents | 2 | 2021 | 2872 | 0.100 |
Why?
|
Language | 1 | 2021 | 1471 | 0.100 |
Why?
|
Clinical Enzyme Tests | 1 | 2011 | 115 | 0.100 |
Why?
|
Genetic Loci | 2 | 2022 | 2575 | 0.100 |
Why?
|
Kidney | 3 | 2022 | 7186 | 0.100 |
Why?
|
Logistic Models | 4 | 2017 | 13408 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 15519 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 4 | 2024 | 17446 | 0.100 |
Why?
|
Fibrinolytic Agents | 2 | 2013 | 2158 | 0.100 |
Why?
|
Cardiology | 1 | 2021 | 1668 | 0.090 |
Why?
|
Treatment Failure | 1 | 2016 | 2618 | 0.090 |
Why?
|
Data Mining | 1 | 2015 | 537 | 0.090 |
Why?
|
Energy Intake | 1 | 2017 | 2148 | 0.090 |
Why?
|
Analysis of Variance | 1 | 2018 | 6365 | 0.090 |
Why?
|
Phospholipases A2 | 2 | 2007 | 203 | 0.090 |
Why?
|
Postoperative Hemorrhage | 1 | 2013 | 413 | 0.090 |
Why?
|
Adipose Tissue | 1 | 2021 | 3279 | 0.080 |
Why?
|
Cat Diseases | 1 | 2008 | 35 | 0.080 |
Why?
|
Receptors, Cell Surface | 2 | 2008 | 2866 | 0.080 |
Why?
|
Oxalates | 1 | 2008 | 105 | 0.080 |
Why?
|
Urinary Calculi | 1 | 2008 | 91 | 0.080 |
Why?
|
Bifidobacterium | 1 | 2008 | 100 | 0.080 |
Why?
|
Leukocytes | 1 | 2016 | 2043 | 0.080 |
Why?
|
Liver Cirrhosis | 1 | 2018 | 1863 | 0.080 |
Why?
|
Dog Diseases | 1 | 2008 | 138 | 0.080 |
Why?
|
Serine Endopeptidases | 1 | 2013 | 1072 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1912 | 0.080 |
Why?
|
Lactobacillus | 1 | 2008 | 189 | 0.080 |
Why?
|
Acute Disease | 3 | 2007 | 7149 | 0.070 |
Why?
|
Research Design | 2 | 2015 | 5987 | 0.070 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2008 | 153 | 0.070 |
Why?
|
Ventricular Function, Left | 1 | 2020 | 3670 | 0.070 |
Why?
|
Necrosis | 1 | 2011 | 1643 | 0.070 |
Why?
|
Disease-Free Survival | 1 | 2017 | 6895 | 0.070 |
Why?
|
Liver | 1 | 2022 | 7474 | 0.070 |
Why?
|
Propensity Score | 1 | 2013 | 1781 | 0.070 |
Why?
|
Erythrocytes | 1 | 2016 | 2455 | 0.070 |
Why?
|
Area Under Curve | 2 | 2008 | 1654 | 0.070 |
Why?
|
Diuretics | 1 | 2009 | 592 | 0.070 |
Why?
|
Energy Metabolism | 1 | 2017 | 2899 | 0.070 |
Why?
|
Spironolactone | 1 | 2009 | 382 | 0.070 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2009 | 641 | 0.070 |
Why?
|
Syndrome | 2 | 2017 | 3251 | 0.070 |
Why?
|
Cerebrovascular Disorders | 1 | 2013 | 1504 | 0.070 |
Why?
|
Epidemiologic Methods | 2 | 2008 | 1364 | 0.070 |
Why?
|
Survival Rate | 2 | 2018 | 12788 | 0.070 |
Why?
|
Coronary Angiography | 2 | 2008 | 4577 | 0.070 |
Why?
|
Glucose | 1 | 2017 | 4397 | 0.060 |
Why?
|
Probiotics | 1 | 2008 | 351 | 0.060 |
Why?
|
Genotype | 2 | 2016 | 12951 | 0.060 |
Why?
|
Enzymes | 1 | 2006 | 266 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2014 | 39050 | 0.060 |
Why?
|
Pyrrolidines | 1 | 2006 | 342 | 0.060 |
Why?
|
Alanine | 1 | 2006 | 572 | 0.060 |
Why?
|
Leukocyte Count | 1 | 2008 | 1588 | 0.060 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2009 | 1240 | 0.060 |
Why?
|
Data Interpretation, Statistical | 1 | 2013 | 2716 | 0.060 |
Why?
|
Emergency Service, Hospital | 6 | 2008 | 7659 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2021 | 19905 | 0.050 |
Why?
|
Liver Diseases | 1 | 2011 | 1253 | 0.050 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2013 | 1536 | 0.050 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2007 | 719 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2007 | 14722 | 0.050 |
Why?
|
Infusions, Subcutaneous | 1 | 2021 | 42 | 0.050 |
Why?
|
Inflammation | 2 | 2012 | 10638 | 0.050 |
Why?
|
Adult | 8 | 2022 | 214055 | 0.050 |
Why?
|
Age Factors | 2 | 2017 | 18370 | 0.050 |
Why?
|
Administration, Intranasal | 1 | 2022 | 446 | 0.050 |
Why?
|
Disease Progression | 1 | 2017 | 13284 | 0.050 |
Why?
|
United States | 4 | 2023 | 69872 | 0.050 |
Why?
|
Gene Frequency | 2 | 2017 | 3588 | 0.040 |
Why?
|
Body Mass Index | 1 | 2017 | 12720 | 0.040 |
Why?
|
Antihypertensive Agents | 1 | 2009 | 2046 | 0.040 |
Why?
|
Uromodulin | 1 | 2019 | 46 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2015 | 3158 | 0.040 |
Why?
|
Eicosapentaenoic Acid | 1 | 2023 | 582 | 0.040 |
Why?
|
Protein Disulfide-Isomerases | 1 | 2020 | 198 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2020 | 365 | 0.040 |
Why?
|
Niacin | 1 | 2019 | 116 | 0.040 |
Why?
|
Lung Diseases | 1 | 2008 | 1886 | 0.040 |
Why?
|
Prospective Studies | 5 | 2023 | 53288 | 0.040 |
Why?
|
Child, Preschool | 1 | 2020 | 41006 | 0.040 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2020 | 611 | 0.040 |
Why?
|
Inheritance Patterns | 1 | 2019 | 340 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2024 | 13989 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2019 | 684 | 0.040 |
Why?
|
Docosahexaenoic Acids | 1 | 2023 | 875 | 0.040 |
Why?
|
Carbohydrate Metabolism | 1 | 2017 | 264 | 0.030 |
Why?
|
Allelic Imbalance | 1 | 2016 | 77 | 0.030 |
Why?
|
Animals | 7 | 2022 | 168757 | 0.030 |
Why?
|
Erythrocyte Indices | 1 | 2016 | 146 | 0.030 |
Why?
|
Algorithms | 1 | 2016 | 13881 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2016 | 403 | 0.030 |
Why?
|
Registries | 2 | 2022 | 8089 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7279 | 0.030 |
Why?
|
Hematocrit | 1 | 2016 | 636 | 0.030 |
Why?
|
Homozygote | 1 | 2019 | 1785 | 0.030 |
Why?
|
Osteoporotic Fractures | 1 | 2019 | 401 | 0.030 |
Why?
|
Medicare | 2 | 2023 | 6566 | 0.030 |
Why?
|
Smoking | 1 | 2011 | 8987 | 0.030 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2020 | 1157 | 0.030 |
Why?
|
Muscle Proteins | 1 | 2020 | 1159 | 0.030 |
Why?
|
Microfilament Proteins | 1 | 2020 | 1152 | 0.030 |
Why?
|
Mendelian Randomization Analysis | 1 | 2020 | 967 | 0.030 |
Why?
|
Cross-Over Studies | 2 | 2011 | 2029 | 0.030 |
Why?
|
Neoplasms | 1 | 2023 | 21683 | 0.030 |
Why?
|
Interleukin-4 | 1 | 2017 | 1147 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1071 | 0.030 |
Why?
|
Platelet Count | 1 | 2016 | 781 | 0.030 |
Why?
|
Quality Control | 1 | 2016 | 841 | 0.030 |
Why?
|
Drug Resistance | 1 | 2019 | 1609 | 0.030 |
Why?
|
Survival Analysis | 1 | 2006 | 10252 | 0.030 |
Why?
|
Spinal Fractures | 1 | 2019 | 696 | 0.030 |
Why?
|
Europe | 1 | 2019 | 3339 | 0.030 |
Why?
|
Internationality | 1 | 2018 | 1003 | 0.030 |
Why?
|
Leadership | 1 | 2021 | 1357 | 0.030 |
Why?
|
Cohort Studies | 3 | 2018 | 40561 | 0.030 |
Why?
|
Cytochrome P-450 CYP1A2 | 1 | 2011 | 68 | 0.030 |
Why?
|
Triglycerides | 1 | 2019 | 2454 | 0.020 |
Why?
|
Hip Fractures | 1 | 2019 | 955 | 0.020 |
Why?
|
Weight Loss | 1 | 2022 | 2622 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2019 | 4740 | 0.020 |
Why?
|
Hemoglobins | 1 | 2016 | 1534 | 0.020 |
Why?
|
Drosophila | 1 | 2017 | 1491 | 0.020 |
Why?
|
Critical Illness | 1 | 2022 | 2670 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 1125 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2020 | 2916 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2017 | 6622 | 0.020 |
Why?
|
Fractures, Bone | 1 | 2019 | 1947 | 0.020 |
Why?
|
Cats | 1 | 2008 | 998 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2020 | 21746 | 0.020 |
Why?
|
Bone Density | 1 | 2019 | 3468 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2020 | 5021 | 0.020 |
Why?
|
Blood Urea Nitrogen | 1 | 2006 | 191 | 0.020 |
Why?
|
Heart Murmurs | 1 | 2006 | 94 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5720 | 0.020 |
Why?
|
Mortality | 1 | 2016 | 2864 | 0.020 |
Why?
|
Dogs | 1 | 2008 | 3912 | 0.010 |
Why?
|
Systole | 1 | 2006 | 958 | 0.010 |
Why?
|
Proteins | 1 | 2017 | 6103 | 0.010 |
Why?
|
Gastrointestinal Tract | 1 | 2008 | 814 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14557 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16365 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25043 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15540 | 0.010 |
Why?
|
Pregnancy | 1 | 2021 | 29144 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 21827 | 0.010 |
Why?
|
Point-of-Care Systems | 1 | 2007 | 1177 | 0.010 |
Why?
|
Body Weight | 1 | 2008 | 4669 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2008 | 8301 | 0.010 |
Why?
|
Linear Models | 1 | 2007 | 5952 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2007 | 8642 | 0.010 |
Why?
|
Heart Rate | 1 | 2006 | 4091 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23403 | 0.010 |
Why?
|
Rats | 1 | 2008 | 24260 | 0.010 |
Why?
|
Young Adult | 1 | 2017 | 56430 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2019 | 77449 | 0.010 |
Why?
|
Mice | 1 | 2017 | 81183 | 0.010 |
Why?
|
Blood Pressure | 1 | 2006 | 8554 | 0.010 |
Why?
|
Adolescent | 1 | 2017 | 85781 | 0.010 |
Why?
|